MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Bankruptcy or Receivership

MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Bankruptcy or Receivership
ITEM 1.03

Story continues below

BANKRUPTCY OR RECEIVERSHIP.

On March 21, 2019, MabVax Therapeutics Holdings, Inc. (the “Company”) filed a voluntary petition for reorganization relief under Chapter 11 of Title 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) (Case No. 19-10603 (CSS)). The Company continues to manage and operate its business as a debtor in possession to Bankruptcy Code Sections 1107 and 1108. The Company intends to sell substantially all of its assets to Section 363 of the Bankruptcy Code in the sixty days following the filing of its Chapter 11 petition under a Bankruptcy Court supervised sales process and, subject to sales proceeds and remaining assets, could convert its case to Chapter 7, at which point a Chapter 7 trustee will be appointed by the Bankruptcy Court.

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

None.

An ad to help with our costs